Cargando…
Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study
(225)Ac-PSMA-617 targeted-therapy has demonstrated efficacy in 75-85% of patients; however, responses are not durable. We aimed to establish translatable mouse models of disseminated prostate cancer (PCa) to evaluate effectiveness of (225)Ac-PSMA-617 at various disease stages. Methods: C4-2, C4-2B,...
Autores principales: | Stuparu, Andreea D., Meyer, Catherine A.L., Evans-Axelsson, Susan L., Lückerath, Katharina, Wei, Liu H., Kim, Woosuk, Poddar, Soumya, Mona, Christine E., Dahlbom, Magnus, Girgis, Mark D., Radu, Caius G., Czernin, Johannes, Slavik, Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052903/ https://www.ncbi.nlm.nih.gov/pubmed/32194823 http://dx.doi.org/10.7150/thno.42228 |
Ejemplares similares
-
Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer
por: Meyer, Catherine, et al.
Publicado: (2023) -
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
por: Lückerath, Katharina, et al.
Publicado: (2018) -
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022) -
The Search for an Alternative to [(68)Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of (18)F-labeled Somatostatin Analog Development
por: Waldmann, Christopher M., et al.
Publicado: (2019) -
Positron Emission Tomography Reporter Genes and Reporter Probes: Gene and Cell Therapy Applications
por: Yaghoubi, Shahriar S., et al.
Publicado: (2012)